---
title: "罗氏通过要约收购购买 89Bio, Inc 的股份"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/263440706.md"
description: "巴塞尔，2025 年 10 月 30 日- 罗氏（SIX: RO, ROG. OTCQX: RHHBY）今天宣布，罗氏全资子公司 Bluefin Merger Subsidiary, Inc.已接受所有有效提交且未有效撤回的股份的付款，作为其对所有已发行普通股的收购要约的一部分"
datetime: "2025-10-30T07:03:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263440706.md)
  - [en](https://longbridge.com/en/news/263440706.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263440706.md)
---

# 罗氏通过要约收购购买 89Bio, Inc 的股份

Basel, 30 October 2025 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today that Roche's wholly owned subsidiary Bluefin Merger Subsidiary, Inc., has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common ...

### 相关股票

- [ETNB.US](https://longbridge.com/zh-CN/quote/ETNB.US.md)
- [RHHBY.US](https://longbridge.com/zh-CN/quote/RHHBY.US.md)

## 相关资讯与研究

- [FOMO2026 ：全球创新药大变局，看懂的人还不多](https://longbridge.com/zh-CN/news/286487435.md)
- [罗氏(ADR)与药品专利池签署协议，扩大流感药物可及性](https://longbridge.com/zh-CN/news/286796802.md)
- [汇率逆风撞上关键药物销售额失色 罗氏卡在专利悬崖与创新药接力的十字路口](https://longbridge.com/zh-CN/news/283781113.md)
- [罗氏同意以 7.5 亿美元收购 PathAI](https://longbridge.com/zh-CN/news/285486754.md)
- [FDA 批准了 Genentech 的 Tecentriq 用于 ctDNA 指导治疗的辅助性肌肉浸润性膀胱癌 | 罗氏 (ADR) 股票新闻](https://longbridge.com/zh-CN/news/286594661.md)